Table 1.
(a) Baseline characteristics of the study cohort, (b) Treatment details for patients in the study cohort.
| (a) Baseline Characteristics of the Study Cohort | |
|---|---|
| Characteristic | N = 65 * |
| Age in years (range) | 67 (37–87) |
| Sex | |
| Female | 29 (45%) |
| Male | 36 (55%) |
| Histology | |
| Adenocarcinoma | 62 (95%) |
| Mucinous | 1 (2%) |
| Acinar cell | 1 (2%) |
| Colloid | 1 (2%) |
| T stage | |
| T1 | 16 (25%) |
| T2 | 41 (63%) |
| T3/T4 | 8 (12%) |
| N stage | |
| N0 | 23 (35%) |
| N1 | 26 (40%) |
| N2 | 16 (25%) |
| Initial pathologic stage | |
| I | 20 (31%) |
| II | 28 (43%) |
| III | 17 (26%) |
| Surgery type | |
| Distal | 12 (18%) |
| Whipple | 53 (82%) |
| Margin status at surgery | |
| Negative (R0) | 34 (52%) |
| Positive (R1) | 17 (26%) |
| Close (R0, tumor < 1 mm) | 14 (22%) |
| Disease-free interval, months (range) | 16 (6–71) |
| (b) Treatment Details for Patients in the Study Cohort | |
| Characteristic | N = 65 * |
| NACT | 27 (42%) |
| NACT regimen | |
| FOLFIRINOX | 13 (48%) |
| gem/Nab-paclitaxel | 12 (43%) |
| FOLFOX | 1 (4%) |
| G-FLIP | 1 (4%) |
| No NACT | 38 |
| Length of NACT, months (range) (N = 27) | 3.22 (0.46–13.96) |
| CA 19-9 at diagnosis, U/mL (range) | 65 (0–3919) |
| CA 19-9 post NACT, U/mL (range) (N = 27) | 50 (0–561) |
| Change in CA 19-9, (N = 27) | −3 (−3358, 135) |
| Salvage for local vs. nodal recurrence | |
| Local | 48 (74%) |
| Local and nodal | 10 (15%) |
| Nodal | 7 (11%) |
| Prior RT | 10 (15%) |
| Ablative RT dose (N = 67 A-RT courses) | |
| 75 Gy/25 fractions | 37 (55%) |
| 67.5 Gy/15 fractions | 23 (34%) |
| Other fractionation schemes | 7 (10%) |
* Unless otherwise stated. Abbreviations: NACT: neoadjuvant chemotherapy; FOLFIRINOX: folinic acid, fluorouracil, irinotecan hydrochloride, and oxaliplatin; FOLFOX: folinic acid, fluorouracil, and oxaliplatin; G-FLIP: gemcitabine, 5-fluorouracil, leucovorin, and cisplatin; RT: radiation therapy.